We performed these analyses on the Kaplan–Meier plotter survival analysis platform, and found that HCC patients in the high SRD5A3 expression group had poorer overall survival (OS, HR = 1.91 (1.34 – 2.73), log-rank test P = 0.00029), relapse-free survival (RFS, HR = 1.59 (1.14 – 2.22), log-rank test P = 0.0055), progression-free survival (PFS, HR = 1.61 (1.20 – 2.17), log-rank test P = 0.0015) and disease specific survival (DSS, HR = 2.13 (1.35 – 3.39), log-rank test P = 0.00098) rates than that in the low SRD5A3 expression group (Figure 5A–5D). The gene discussed is SRD5A3; the disease is hepatocellular carcinoma.